Evotec

Pioneering Drug Discovery

Founded 1993 Germany

Hamburg, Germany 4683 employees Grant Total: $668.31M Biotechnology, Health Care +2

General Information

Company Name Evotec

Founded Year 1993

Location

Hamburg, Germany

Founders / Decision Makers

Employees 4683

Industries Biotechnology, Health Care, Health and Wellness +1

Funding Stage Grant

Business Model B2B, B2G

Revenue Model Service Fee, Project Based, Performance Based

Offices as of Nov 2026

Hamburg, Germany Branford, United States Princeton, United States Nether Alderley, United Kingdom Neuried, Germany Verona, Italy

Social

BounceWatch is an independent company data service, not affiliated with Evotec. To contact Evotec, visit evotec.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Evotec compare?

A PDF of Evotec and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Evotec soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

From the desk

Is Evotec on your competitive set?

Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.

Book a 7-day Readout

Discover More

Germany Market

Market Signals All Companies

Biotechnology

Industry Signals All Companies in Germany

Evotec Alternatives

All Signals Trend Reports

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Revenue Metrics Nov 05, 2026

Evotec announced Q3 and first nine months 2026 financial results, with group revenue reaching €164.9 million in the third quarter.

Event Participation Nov 04, 2026

Evotec will present its work on iPSC-derived CAR γδ T cells at Cell & Gene Therapy International Europe 2026 in Berlin.

Homepage Update Nov 02, 2026

Significant changes detected on company website (32.8% content change).

In The News Oct 25, 2026

Featured on Börse Global: Evotec Aktie: Hold-Bremse trotz Überraschung?

In The News Oct 24, 2026

Featured on Börse Social: Evotec und Sartorius vs. GlaxoSmithKline und Medigene – kommentierter KW 43 Peer...

In The News Oct 24, 2026

Featured on Finanztrends: Evotec Aktie: Mubadala trennt sich von allen Anteilen

+2 more signals in last 30 days

Evotec a competitor of yours? Have our desk watch it

AI Insight

Bounce Watch AI

6 days ago

Evotec recently experienced significant investor dynamics with Mubadala divesting all shares, yet simultaneously demonstrated robust operational activity through the launch of a T-Cell Immunogenicity Risk Panel and reporting €164.9 million in Q3 revenue. The appointment of a new Chief Scientific Officer and exploratory partnership discussions for RNA medicine programs indicate a strategic push into advanced therapeutic modalities and enhanced service offerings. These moves highlight a company actively evolving its scientific and commercial strategies despite shifts in its investor base.

Signal Types

Investor Exit Product Launch Revenue Growth Leadership Change Strategic Partnerships

Strategic Labels

Portfolio Expansion Leadership Realign Market Adaptation

Next Move: Expansion

Impact: 9/10

Ideal For: Life Sciences Investors — Post-IPO Equity

About Evotec

Evotec, founded in 1993, is a Germany-based biotechnology company that excels in pioneering drug discovery and development. Known for its slogan, "Pioneering Drug Discovery," Evotec operates through flexible business models by forging partnerships with pharmaceutical companies, biotechs, foundations, and government agencies. Their comprehensive approach, termed as the Pipeline Co-Creation model, ensures high-quality collaborations across all phases of drug discovery and development.

Evotec's mission is to enhance disease understanding through data-driven insights and AI, thereby increasing the success probability of novel therapies. Their vast team of over 4,000 scientists engages concurrently with multiple partners, delivering integrated research and development solutions. The company also offers tailored CRO/CDMO-like services to biopharma innovators.

The latest financial endorsement, a $2.50M grant from the Bill & Melinda Gates Foundation, underscores the trust placed in Evotec's innovative capabilities and potential to impact global healthcare positively.

Business keywords: Drug Discovery, Pharmaceutical Collaboration, Pipeline Co-Creation, Data-Driven Disease Understanding, AI-Enabled Research, CRO/CDMO Services, Integrated Drug Discovery, Development Partnerships, Licensing of Drug Candidates, Clinical Proof of Concept, CNS Research, Oncology, Neurosciences, Metabolic Disease

Services & Products

Drug discovery and development

Biologics manufacturing

Integrated R&D services

CRO essentials

Target Customers

Pharmaceutical companies Biotechnology firms Healthcare providers Research institutions

Funding Rounds & Investors (14)

View All

Funding Stage	Amount	Investors	Lead Investors	Date
Grant	$2.50M	1	Bill & Melinda Gates Foundation	19 Dec 2023
Grant	$1.70M	1	Open Philanthropy	02 Jun 2023
Grant	$6.60M	1	Bill & Melinda Gates Foundation	24 Mar 2023
Post IPO Debt	€150.00M	1	European Investment Bank	10 Feb 2023
Grant	€7.50M	1	German Federal Ministry of Education and Research	03 Jan 2022
Grant	$18.00M	1	Bill & Melinda Gates Foundation	16 Dec 2021
Grant	Undisclosed	1	Bill & Melinda Gates Foundation	19 Oct 2020
Post IPO Equity	€250.00M	2	Novo Holdings, Mubadala	13 Oct 2020
Grant	$2.91M	1	CARB-X	11 Aug 2020
Grant	$23.80M	-		10 Jun 2019

View All 14 Funding Rounds

Latest News

View All

Evotec Aktie: Hold-Bremse trotz Überraschung?

Börse Global Oct 25, 2026

Evotec Aktie: Mubadala trennt sich von allen Anteilen

Finanztrends Oct 24, 2026

Evotec und Sartorius vs. GlaxoSmithKline und Medigene – kommentierter KW 43 Peer Group Watch Pharma, Chemie, Biotech, Arznei & Gesundheit

Börse Social Oct 24, 2026

Evotec stock falls 3.57 percent after leadership change

AD HOC NEWS Oct 03, 2026

11,7 Prozent Plus: Darum kennt die Evotec-Aktie gerade kein Halten

Wallstreet Online Oct 03, 2026

Evotec Aktie: Plectonic-Kooperation vereinbart

Finanztrends Oct 03, 2026

Evotec Alternatives & Competitors

View All Alternatives

Evotec vs

ONCOCROSS Co., Ltd. Korea South

AI, drug discovery development, biotechnology, indication expansion, rare disease, intractable disea...

IPO

18 employees

Biotechnology, Pharmaceutical

Evotec vs

Syntekabio Inc. United States

AI Platform for Drug Discovery & Precision Medicine (226330:KOSDAQ)

Series C

36 employees

Biotechnology, Health Care

Evotec vs

1910 Genetics United States

Advancing small and large molecule drug discovery with a multimodal AI platform powered by laborator...

Venture round

37 employees

AI, Biotechnology

Also compare with:

AnaBios Corporation

TMC Pharma Services Ltd View all alternatives

FAQ About Evotec

Pioneering Drug Discovery

Evotec was founded in 1993.

Evotec is headquartered in Hamburg, Germany. As of Nov 2026, it also has offices in Branford, United States, Princeton, United States, Nether Alderley, United Kingdom, Neuried, Germany and Verona, Italy.

Evotec operates in Biotechnology, Health Care, Health and Wellness and Pharmaceutical. Its work centres on Drug Discovery, Pharmaceutical Collaboration, Pipeline Co-Creation and Data-Driven Disease Understanding. Its customers include Pharmaceutical companies, Biotechnology firms and Healthcare providers.

Evotec has a B2B and B2G business model. Its revenue comes from Service Fee, Project Based and Performance Based.

Evotec has approximately 4683 employees.

Evotec has completed 14 funding rounds, raising a total of $668.31M. The latest funding stage is Grant.

Evotec offers: Drug discovery and development, Biologics manufacturing, Integrated R&D services, CRO essentials.

Top alternatives and competitors to Evotec include ONCOCROSS Co., Ltd., Syntekabio Inc., 1910 Genetics, AnaBios Corporation, Drug Discovery & Development. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Evotec and ONCOCROSS Co., Ltd. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Evotec, https://www.bouncewatch.com/company/evotec, updated 8 November 2026. When citing, please name BounceWatch and link this page.

Evotec

General Information

Discover More

What changed at Evotec recently?

AI Insight

About Evotec

Services & Products

Target Customers

Funding Rounds & Investors (14)

Latest News

Evotec Alternatives & Competitors

FAQ About Evotec